Interestingly, we found that the proportion and absolute counting of CD3+, CD14+, and CD3-CD16+CD56+ cells in patients with thyroid cancer are the closest to those in healthy groups, whereas patients with liver cancer and cholangiocarcinoma are quite different from those in healthy groups, which may indicate that patients with thyroid cancer have relatively light immunosuppression, low metastatic ability, and are treatable. The gene discussed is NCAM1; the disease is thyroid cancer.